Cleerly Stock

cleerlyhealth.comHealthcare / Digital HealthFounded: 2016Funding to Date: $286.4MM

Cleerly, founded in 2016, is a digital healthcare company using AI to create a new standard of care for heart disease. The Cleerly platform is aiming to differentiate itself by using AI to measure plaque build-up in the heart’s arteries versus using indirect markers, like risk factors and symptoms of disease to help clinicians identify and define heart disease earlier and provide personalized treatment plans to patients.

Register To Buy and Sell Shares

For more details on financing and valuation for Cleerly, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Cleerly’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cleerly.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

James Min MD
Founder, Chief Executive Officer, President & Board Member
Krissy Wright
Chief Financial Officer
Joseph Jasser MD
Chief Operating Officer
Kimberly McCombs
Chief Strategy Officer
Nick Nieslanik
Chief Technology Officer
Zach Hong
Chief Compliance Officer & General Counsel
Jim Hartman
Chief Revenue Officer
Udo Hoffmann MD
Chief Scientfic Officer
James Earls MD
Chief Medical Officer
Kristin Binns
Chief Marketing & Communications Officer

Board Members

Glenn Steele Ph.D
Justin Klein MD
Vensana Capital
Tripp Peake III
Vijay Lathi
New Leaf Venture

Frequently Asked Questions About Cleerly’s Stock

Can you buy Cleerly’s stock?
Cleerly is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cleerly’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Cleerly’s stock?
Yes, you can sell stock of a private company like Cleerly. Forge can help you sell your Cleerly stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Cleerly’s stock price?
Cleerly is a privately held company and therefore does not have a public stock price. However, you may access Cleerly’s private market stock price with Forge Data.
What is Cleerly’s stock ticker symbol?
Cleerly does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Cleerly Uses an AI-Based Digital Platform to Transform Heart Disease Diagnosis
Digital healthcare company Cleerly is leveraging AI technology to revolutionize the diagnosis of heart disease. Their platform uses imaging and AI to detect atherosclerosis at an early stage, enabling more personalized and effective treatment plans. The company is also sponsoring a trial, TRANSFORM, to validate the efficacy of this personalized care strategy.
How AI is detecting heart attack risk and aiming to outsmart America’s No. 1 killer
Cardiologist James Min, former professor at Weill Cornell Medical College and director of the Dalio Institute of Cardiovascular Imaging at New York-Presbyterian, founded Cleerly to find a better way to assess heart health, by applying AI to the problem, cutting down on the time it takes to flag issues and ultimately reach his goal of a “heart-attack free” world.
Cleerly raises nearly $200 mln in fundraise led by T. Rowe Price, Fidelity
Cleerly, a New York-based health tech startup, has raised $192 million in a funding round led by investment firms T. Rowe Price (TROW.O) and Fidelity Management & Research Company LLC.
Updated on: Apr 22, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.